arbiter
JournalsAccount

Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the U.S., 2015–2015

Keith M. Drake & Rena M. Conti

Journal of Health Politics, Policy and Law2026https://doi.org/10.1215/03616878-12513812article
ABDC A
Weight
0.50

Abstract

Although biosimilars are still relatively rare, the patent litigation structure does not appear to be slowing competitive entry for biologics relative to small molecule drugs. Biosimilar competition may become more common as biologics advance in their life cycle and the regulations are brought to bear.

Open via your library →

Cite this paper

https://doi.org/https://doi.org/10.1215/03616878-12513812

Or copy a formatted citation

@article{keith2026,
  title        = {{Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the U.S., 2015–2015}},
  author       = {Keith M. Drake & Rena M. Conti},
  journal      = {Journal of Health Politics, Policy and Law},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1215/03616878-12513812},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the U.S., 2015–2015

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.